Patients with epidermal growth factor receptor (EGFR) positive non-small cell lung cancer (NSCLC) show improved response rates when treated with tyrosine kinase inhibitors (TKIs) such as erlotinib. However, standard daily dosing of erlotinib often does not reach therapeutic concentrations within the cerebrospinal fluid (CSF), resulting in progression of central nervous system (CNS) disease. Intermittent, high dose administration of erlotinib reaches therapeutic concentrations within the CSF and is well-tolerated in patients.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2lq3g6Q
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
International Journal of Engineering Research and Applications (IJERA) is an open access online peer reviewed international journal that pub...
-
You could soon get an even more immersive VR experience thanks to the Ambiotherm plug in, which exposes you to the elements of your virtual...
-
Study of Sharp Corner Cutting In Wire EDM Thesis submitted in accordance with The test specimens have been cut by using different wire-cut E...
-
Abstract T cell immunoglobulin and mucin domain 3 (Tim-3) is a critical regulatory molecule found on activated Th1 cells, exhausted CD8 + ...
-
Join in on the conversation about GCSE Statistics Coursework Help on the TSR community forums. from #AlexandrosSfakianakis via Alexandros ...
-
CFS, also known as ME, may be caused by the body switching from fully breaking down carbohydrates to using other energy sources, bringing o...
-
We provide MLA, Harvard, Chicago/Turabian and APA style formatting for your academic papers. Just specify what style you require and we will...
-
Visit this site dedicated to Valentine from 100 Valentine Poems for your special person. Famous Valentine Poems from the Worlds greatest Poe...
-
Planta Med DOI: 10.1055/s-0043-106050 Glucose homeostasis is maintained by antagonistic hormones such as insulin and glucagon as well as ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου